BGI Genomics Co., Ltd. (SHE:300676)
China · Delayed Price · Currency is CNY 40.28
-0.94 (-2.28%)
Apr 28, 2026, 3:04 PM CST
BGI Genomics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -573.48 | -616.66 | -902.69 | 92.9 | 802.77 | 1,462 |
Depreciation & Amortization | 491.5 | 491.5 | 483.53 | 436.84 | 453.07 | 370.6 |
Other Amortization | 129.08 | 129.08 | 71.64 | 47.4 | 34.61 | 25.82 |
Loss (Gain) From Sale of Assets | 0.34 | 0.34 | 0.63 | -2.76 | -0.11 | 3.88 |
Asset Writedown & Restructuring Costs | 113.96 | 113.96 | 193.76 | 9.25 | 209.24 | 102.24 |
Loss (Gain) From Sale of Investments | -1.67 | -1.67 | 87.41 | 33.07 | -388.21 | -260.29 |
Provision & Write-off of Bad Debts | 285.4 | 285.4 | 197.1 | 66.41 | 185.1 | 104.56 |
Other Operating Activities | 172.05 | -0.51 | 14.52 | 82.53 | 325.54 | 130.7 |
Change in Accounts Receivable | -244.44 | -244.44 | -438.84 | 736.49 | -1,086 | 254.15 |
Change in Inventory | 86.42 | 86.42 | -34.2 | 103.78 | 46.25 | 169.94 |
Change in Accounts Payable | -234.77 | -234.77 | 284.49 | -1,345 | -484.64 | 147.51 |
Change in Other Net Operating Assets | -57.85 | -57.85 | 115.5 | 122.81 | 22.85 | - |
Operating Cash Flow | 152.53 | -63.21 | 95.72 | 408.77 | 130.88 | 2,476 |
Operating Cash Flow Growth | - | - | -76.58% | 212.31% | -94.71% | -31.27% |
Capital Expenditures | -508.64 | -505.92 | -529.48 | -1,236 | -1,267 | -383.52 |
Sale of Property, Plant & Equipment | 6.31 | 6.05 | 0.56 | 2.72 | 0.33 | 0.71 |
Cash Acquisitions | - | - | - | - | 5.2 | - |
Divestitures | -12 | -12 | - | - | -0.01 | 5.91 |
Investment in Securities | -273.16 | -586.64 | 116.67 | -763.71 | 569.72 | -2,069 |
Other Investing Activities | 69.7 | 73.32 | 97.83 | 246.64 | 111.31 | 153.44 |
Investing Cash Flow | -717.8 | -1,025 | -314.42 | -1,751 | -580.07 | -2,292 |
Long-Term Debt Issued | - | 570.96 | 192.8 | 251.68 | 20 | 5 |
Total Debt Issued | - | 570.96 | 192.8 | 251.68 | 20 | 5 |
Long-Term Debt Repaid | - | -473.02 | -94.96 | -78.77 | -780.21 | -690.2 |
Total Debt Repaid | -494.33 | -473.02 | -94.96 | -78.77 | -780.21 | -690.2 |
Net Debt Issued (Repaid) | -494.33 | 97.94 | 97.84 | 172.91 | -760.21 | -685.2 |
Issuance of Common Stock | 69.2 | 69.2 | 53.08 | 82.85 | - | 2,003 |
Repurchase of Common Stock | - | - | -780.52 | - | -336.74 | - |
Common Dividends Paid | -18.11 | -17.28 | -50.36 | -416.73 | -167.13 | -177.78 |
Other Financing Activities | 3.06 | - | -3.18 | -105.91 | 69.54 | -102.79 |
Financing Cash Flow | -440.19 | 149.86 | -683.15 | -266.88 | -1,195 | 1,037 |
Foreign Exchange Rate Adjustments | -19.73 | -1.55 | 45.12 | 32.82 | 279.38 | -139.91 |
Net Cash Flow | -1,025 | -940.1 | -856.72 | -1,576 | -1,364 | 1,081 |
Free Cash Flow | -356.11 | -569.14 | -433.76 | -827.62 | -1,136 | 2,093 |
Free Cash Flow Growth | - | - | - | - | - | -36.62% |
Free Cash Flow Margin | -9.27% | -15.36% | -11.22% | -19.03% | -16.10% | 30.93% |
Free Cash Flow Per Share | -0.85 | -1.37 | -1.05 | -2.01 | -2.77 | 5.08 |
Cash Income Tax Paid | 139.25 | 134.59 | 204.03 | 144.8 | 336.02 | 419.82 |
Levered Free Cash Flow | -315.87 | -486.01 | -1,065 | -467.62 | -619.14 | 1,633 |
Unlevered Free Cash Flow | -292.22 | -463.49 | -1,033 | -410.4 | -556.16 | 1,698 |
Change in Working Capital | -464.66 | -464.66 | -50.19 | -356.87 | -1,491 | 537.08 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.